MMMakoto Murata

Makoto Murata

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Makoto Murata has a total of 309 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Adverse impact of deletion of the chromosome 6 on clinical outcomes after allogeneic hematopoietic transplantation

    by Masaharu Tamaki, Yoshitaka Zaimoku, Shunto Kawamura, Kentaro Fukushima, Ryu Yanagisawa, Masahiro Hirayama, Noriko Doki, Takahiro Fukuda, Tetsuya Nishida, Yuta Hasegawa, et al.

    Graft-versus-leukemia (GVL) effect is mainly mediated by alloreactive T and NK cells through human leukocyte antigen (HLA). Although most HLA genes are located on the short arm of chromosome 6, the clinical significance of deletion of the short arm of chromosome 6 (del6p) which could attenuate the GVL effect has not been elucidated. We investigated impact of del6p at the diagnosis of hematological malignancies on allogeneic cell transplantation, using a Japanese registry database. Del6p was highly associated with additional chromosomal abnormalities. In the univariate analysis, the del6p group showed a higher incidence of relapse at 2 years among the entire cohort (2y-relapse 48.3% vs 25.7%, P <0.001). Multivariate analysis confirmed that del6p was significantly associated with an increased risk of relapse (HR 1.30 [95% CI: 1.02-1.65], P = 0.036). The del6p group also tended to be associated with relapse, when focusing on patients with complex karyotype (HR 1.25 [95% CI: 0.97-1.60], P = 0.079). Additionally, the impact of del6p on relapse was more evident in the HLA-mismatched than in the HLA-matched cohort. These results suggest that del6p at diagnosis might attenuate the GVL effect through HLA status.

  • Impact of Donor Age on Transplant Outcomes in Matched Unrelated Donor Transplantation for Myelofibrosis

    by Kazuki Sakatoku, Yutaka Shimazu, Makoto Murata, Tetsuya Nishida, Shuichi Shirane, Keisuke Kataoka, Naoyuki Uchida, Masashi Sawa, Jun Ishikawa, Masaya Maegaki, et al.

  • Open Access

    Retrospective comparison of mesenchymal stromal cells and antithymocyte globulin as second-line therapy for acute graft-versus-host disease

    by Makoto Murata, Seitaro Terakura, Junya Kanda, Naoyuki Uchida, Satoshi Yoshihara, Takahiro Fukuda, Keisuke Kataoka, Atsushi Wake, Noriko Doki, Shuichi Ota, et al.

  • Open Access

    The role of HLA transcription in unrelated hematopoietic cell transplantation

    by Satoko Morishima, Takashi Shiina, Fumihiro Azuma, Shohei Tomori, Noriko Doki, Tetsuya Nishida, Takahiro Fukuda, Tetsuya Eto, Keisuke Kataoka, Yuta Hasegawa, et al.

    Expression levels of HLA are associated with susceptibility to various diseases and outcomes after allogeneic hematopoietic cell transplantation (HCT). However, there has been no comprehensive analysis of the effect of the expression levels of the HLA-A, -B, -C, and -DRB1 alleles in unrelated HCT (UR-HCT). Using the capture RNA-sequencing method, we analyzed the gene expression of HLA alleles in 443 healthy donors and determined allele-specific transcription (AST) levels. We assigned median AST (M-AST) levels to HLA typing data of patients who received a transplant from unrelated donors matched for HLA-A, -B, -C, and -DRB1 alleles, using transplant registry data. All 6084 patients were divided into low, middle, and high tertile groups according to the distribution of the sum of the 2 alleles of the M-AST level for each HLA locus and the sum of the 8 alleles of the M-AST level for all 4 loci. The risk of grade 2 to 4 acute graft-versus-host disease was significantly higher in the middle group (hazard ratio [HR], 1.11; P = .044) and high group (HR, 1.20; P< .001) than in the low group for the sum of the HLA-A, -B, -C, and -DRB1 loci. Similar results were observed at the HLA-A, -B, -C, and -DRB1 loci. Higher transcription levels were also associated with a lower risk of relapse at the HLA-B, -C, and -DRB1 loci. Our data suggest that high transcription levels of patient and/or donor HLA may evoke strong alloimmune responses and affect UR-HCT outcomes.

  • Open Access

    Adjustment of low-dose ATG exposure improves outcomes in allogeneic hematopoietic stem cell transplantation: a prospective multicenter study

    by Shihomi Kuwano, Seitaro Terakura, Kanae Imai, Shiho Hirano, Hirofumi Yokota, Yuki Takeuchi, Takahiko Sato, Ryo Hanajiri, Masashi Sawa, Yuichiro Inagaki, et al.


  • Open Access

    Cullin-5 deficiency promotes chimeric antigen receptor T cell effector functions potentially via the modulation of JAK/STAT signaling pathway

    by Yoshitaka Adachi, Seitaro Terakura, Masahide Osaki, Yusuke Okuno, Yoshitaka Sato, Ken Sagou, Yuki Takeuchi, Hirofumi Yokota, Kanae Imai, Peter Steinberger, et al.

    Chimeric antigen receptor (CAR) T cell is a promising therapy for cancer, but factors that enhance the efficacy of CAR T cell remain elusive. Here we perform a genome-wide CRISPR screening to probe genes that regulate the proliferation and survival of CAR T cells following repetitive antigen stimulations. We find that genetic ablation of CUL5, encoding a core element of the multi-protein E3 ubiquitin-protein ligase complex, cullin-RING ligase 5, enhances human CD19 CAR T cell expansion potential and effector functions, potentially via the Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway. In this regard, CUL5 knockout CD19 CAR T cells show sustained STAT3 and STAT5 phosphorylation, as well as delayed phosphorylation and degradation of JAK1 and JAK3. In vivo, shRNA-mediated knockdown of CUL5 enhances CD19 CAR T treatment outcomes in tumor-bearing mice. Our findings thus imply that targeting CUL5 in the ubiquitin system may enhance CAR T cell effector functions to enhance immunotherapy efficacy.


  • Open Access

    Supplementary Figure S3 from Dual CAR-T Cells Targeting CD19 and CD37 Are Effective in Target Antigen Loss B-cell Tumor Models

    by Kanae Imai, Yuki Takeuchi, Seitaro Terakura, Shingo Okuno, Yoshitaka Adachi, Masahide Osaki, Koji Umemura, Ryo Hanajiri, Kazuyuki Shimada, Makoto Murata, et al.

    Supplemental Figure S3. Analysis of differentiation markers of CAR-T cells. Each CAR-T cells and tEGFR-T cells were stimulated with CD19/CD37 positive Raji cells at a 1:5 ratio every 7 days and stained for CD62L, CD45RA, CCR7, CD27 and CD28. A, B, Summary data of the percentage of CD45RA-/CD62L+ central memory T (TCM) cell fraction (A) and CD45RA-/CD62L- effecter memory T (TEM) cell fraction (B). C–E, Summary data of the percentage of CCR7-/CD27+/CD28+ early TEM cell fraction (C), CCR7-/CD27+/CD28- late TEM cell fraction (D) and CCR7-/CD27-/CD28- effecter T cell fraction (E). Data represent mean ± SEM from five different donors (two-way ANOVA, *p < 0.05, **p < 0.01, ***p < 0.001).

  • Open Access

    Supplementary Figure S3 from Dual CAR-T Cells Targeting CD19 and CD37 Are Effective in Target Antigen Loss B-cell Tumor Models

    by Kanae Imai, Yuki Takeuchi, Seitaro Terakura, Shingo Okuno, Yoshitaka Adachi, Masahide Osaki, Koji Umemura, Ryo Hanajiri, Kazuyuki Shimada, Makoto Murata, et al.

    Supplemental Figure S3. Analysis of differentiation markers of CAR-T cells. Each CAR-T cells and tEGFR-T cells were stimulated with CD19/CD37 positive Raji cells at a 1:5 ratio every 7 days and stained for CD62L, CD45RA, CCR7, CD27 and CD28. A, B, Summary data of the percentage of CD45RA-/CD62L+ central memory T (TCM) cell fraction (A) and CD45RA-/CD62L- effecter memory T (TEM) cell fraction (B). C–E, Summary data of the percentage of CCR7-/CD27+/CD28+ early TEM cell fraction (C), CCR7-/CD27+/CD28- late TEM cell fraction (D) and CCR7-/CD27-/CD28- effecter T cell fraction (E). Data represent mean ± SEM from five different donors (two-way ANOVA, *p < 0.05, **p < 0.01, ***p < 0.001).

  • Open Access

    Data from Dual CAR-T Cells Targeting CD19 and CD37 Are Effective in Target Antigen Loss B-cell Tumor Models

    by Kanae Imai, Yuki Takeuchi, Seitaro Terakura, Shingo Okuno, Yoshitaka Adachi, Masahide Osaki, Koji Umemura, Ryo Hanajiri, Kazuyuki Shimada, Makoto Murata, et al.

    Chimeric antigen receptor T (CAR-T) cells targeting multiple antigens (Ag), may reduce the risk of immune escape following the loss of the target Ag and further increase the efficacy of treatment. We developed dual-targeting CAR-T cells that target CD19 and CD37 Ags and evaluated their antitumor effects. CD19/CD37 dual CAR-T cells were generated using cotransduction and simultaneous gene transfer of two types of lentiviral vectors transferring CD19CAR or CD37CAR genes, including the intracellular domains of CD28 and CD3ζ signaling domains. These dual CAR-T cells contained three fractions: CD19/CD37 bispecific CAR-T cells, single CD19CAR-T cells, and single CD37CAR-T cells. In the functional evaluation of CAR-T cells in vitro, CD19/CD37 dual CAR-T cells showed adequate proliferation and cytokine production in response to CD19 and CD37 antigen stimulation alone or in combination. Evaluation of intracellular signaling revealed that dual CAR-T cell–mediated signals were comparable with single CAR-T cells in response to CD19- and CD37-positive B-cell tumors. Although the cytotoxicity of CD19/CD37 dual CAR-T cells in both CD19- and CD37-positive B-cell tumors was similar to that of single CD19 and CD37CAR-T cells, against CD19 and CD37 Ag-heterogeneous tumor, dual CAR-T cells demonstrated significantly superior tumor lysis compared with single CAR-T cells. Furthermore, CD19/CD37 dual CAR-T cells effectively suppressed Ag-heterogeneous Raji cells in a xenograft mouse model. Collectively, these results suggest that CD19/CD37 dual CAR-T cells may be effective target-Ag-loss B-cell tumor models in vitro and in vivo, which represents a promising treatment for patients with relapsed/refractory B-cell malignancies.

  • Open Access

    Supplementary FIgure S2 from Dual CAR-T Cells Targeting CD19 and CD37 Are Effective in Target Antigen Loss B-cell Tumor Models

    by Kanae Imai, Yuki Takeuchi, Seitaro Terakura, Shingo Okuno, Yoshitaka Adachi, Masahide Osaki, Koji Umemura, Ryo Hanajiri, Kazuyuki Shimada, Makoto Murata, et al.

    Supplemental Figure S2. Evaluation of cytokine production against tumor cells isolated from patients who relapsed after CAR-T cell therapy. A, Expression of CD19, CD20, and CD37 in diffuse large B-cell lymphoma cells from a relapsed patient after a treatment with tisagenlecleucel. B, Intracellular IL-2 or IFN-γ positive cells after stimulation with the patient tumor cells at an E:T ratio 1:1 for 4 h.